Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine

References

• Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–e1582. doi:10.4088/JCP.15m0999726717533
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–457. doi:10.1016/j.schres.2013.11.04124412468
   PubMed Web of Science ®Google Scholar
• Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–373. doi:10.1097/JCP.000000000000034626075487
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75. doi:10.1111/bdi.1223825056368
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–292. doi:10.4088/JCP.14m0908125562205
   PubMed Web of Science ®Google Scholar
• Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302. doi:10.1016/j.jad.2014.11.01825532076
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–271. doi:10.1016/j.schres.2016.06.03027427558
   PubMed Web of Science ®Google Scholar
• Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113. doi:10.1016/S0140-6736(17)30060-028185672
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173(3):271–281. doi:10.1176/appi.ajp.2015.1502016426541814
   PubMed Web of Science ®Google Scholar
• Earley W, Burgess M, Rekeda L, et al. Cariprazine treatment of bipolar I depression: a randomized, double blind, placebo-controlled phase 3 study. Presented at: Annual Meeting of the American Society of Clinical Psychopharmacology; 5 29, 2018; Miami Beach, FL.
   Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371–378. doi:10.4088/JCP.15m1007027046309
   PubMed Web of Science ®Google Scholar
• Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–340. doi:10.1124/jpet.109.16043220093397
   PubMed Web of Science ®Google Scholar
• Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011;218(3):579–587. doi:10.1007/s00213-011-2343-z21625907
   PubMed Web of Science ®Google Scholar
• Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925–935. doi:10.1016/j.neuint.2011.07.00221767587
   PubMed Web of Science ®Google Scholar
• Kiss B, Horti F, Bobok A. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. Schizophr Res. 2012;136(Suppl1):S190,poster #116. doi:10.1016/S0920-9964(12)70588-1
   Web of Science ®Google Scholar
• Girgis RR, Slifstein M, D’Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl). 2016;233(19–20):3503–3512. doi:10.1007/s00213-016-4382-y27525990
   PubMed Web of Science ®Google Scholar
• Girgis RR, Abi-Dargham A, Slifstein M, et al. In vivo dopamine D3 and D2 receptor occupancy profile of cariprazine versus aripiprazole: a PET study. Neuropsychopharmacology. 2017;42:S476–S652.
   Web of Science ®Google Scholar
• McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology. 2010;35(8):1826–1835. doi:10.1038/npp.2010.5020410873
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193–206. doi:10.1517/17425255.2013.75921123320989
   PubMed Web of Science ®Google Scholar
• Kirschner N, Kapás M, Colella G, et al. Metabolite profiles of cariprazine in plasma, urine, feces, and bile of rats. Presented at: 16th North American Meeting of the International Society for the Study of Xenobiotics; 10 18–22, 2009; Baltimore, MD.
   Google Scholar
• Meszaros GP, Agai-Csongor E, Kapas M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal. 2008;48(2):388–397. doi:10.1016/j.jpba.2007.12.01618242914
   PubMed Web of Science ®Google Scholar
• Kirschner N, Gémesi L, Vastag M, et al. In vitro metabolism of RGH-188. Drug Metab Rev. 2008;40(Supplement1):128–129 (abstract No. 182).
   Google Scholar
• Tadori Y, Forbes RA, McQuade RD, Kikuchi T. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011;668(3):355–365. doi:10.1016/j.ejphar.2011.07.02021816144
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kubota T, Iwakaji A, Imada M, Kapas M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Dev Ther. 2016;10:327–338. doi:10.2147/DDDT.S95100
   PubMed Web of Science ®Google Scholar
• Periclou A, Phillips L, Bihorel S, et al. Characterization of population pharmacokinetics of cariprazine and its major metabolites. Presented at: 169th Annual Meeting of the American Psychiatric Association; 5 14–18, 2016; Atlanta, GA.
   Google Scholar
• Kurko D, Bekes Z, Gere A, et al. Comparative pharmacology of adrenergic alpha(2C) receptors coupled to Ca(2+) signaling through different Galpha proteins. Neurochem Int. 2009;55(7):467–475. doi:10.1016/j.neuint.2009.04.01519426776
   PubMed Web of Science ®Google Scholar
• Kiss B, Horti F, Bobok A. In vitro and in vivo comparison of [(3)H](+)-PHNO and [(3)H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D(3) from D(2) receptor sites. Synapse. 2011;65(6):467–478. doi:10.1002/syn.2086720936685
   PubMed Web of Science ®Google Scholar
• Delcourte S, Ashby CR Jr, Rovera R, et al. The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity. CNS Neurosci Ther. 2018. doi:10.1111/cns.12867
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099–3108.4202581
   PubMed Web of Science ®Google Scholar
• Craig DA. The Cheng-Prusoff relationship: something lost in the translation. Trends Pharmacol Sci. 1993;14(3):89–91.8488569
   PubMed Web of Science ®Google Scholar
• Mészáros GP, Terjéki Bolf E, Gémesi L, Kapáas M, Tihanyi K, Szombathelyi Z. Pharmacokinetics of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in rats and dogs. Eur Neuropsychopharmacol. 2008;18:S456–S457. doi:10.1016/S0924-977X(08)70676-X
   Web of Science ®Google Scholar
• Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20(10):788–796. doi:10.1093/ijnp/pyx03828531264
   PubMed Web of Science ®Google Scholar
• Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226(1):91–100. doi:10.1007/s00213-012-2896-523079899
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25(5–6):567–574. doi:10.1097/FBP.000000000000007025083572
   PubMed Web of Science ®Google Scholar
• Correll CU, Jain R, Periclou A, et al. Potential relationship between relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia. Presented at: 171st Annual Meeting of the American Psychiatric Association; 5 5–9, 2018; New York City, NY.
   Google Scholar